Dr. Daniel Bednárik Heads NexImmune's Molecular Engineering & Protein Design effort.

Share Article

Dr. Daniel Bednárik heads NexImmune's Molecular Engineering & Protein Design programs for AIM-ACT and AIM-101. His team will focus on development and translation of the company's proprietary AIM technology from the bench to the bedside.

Dr. Bednárik is leading the Molecular Engineering & Protein Design Dept. for NexImmune - He has over 30 years experience as a translational scientist and executive specializing in moving promising technologies into product development. He was previously Vice President, Molecular Engineering Unit at Intrexon Corp. where he led a team of scientists developing innovative methods for cellular therapies for cancer. Prior to that, Dr. Bednárik held senior positions at Cardiome Pharma Corporation, Artesian Therapeutics, Inc., and Gene Logic, Inc. and led various projects focused on translational medicine spanning several therapeutic areas including cancer and cardiovascular diseases. Among other accomplishments he created the largest known cardiovascular transcriptomic gene expression database for Gene Logic, Inc. He was also the recipient of a $1.7M DARPA contract in 2006 for the development of a novel non-host method for rapid vaccine manufacture. Earlier in his career, Dr. Bednárik served as a Senior Scientist for Human Genome Sciences (HGS) and completed a post-doctoral fellowship at The Johns Hopkins University Oncology Center.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Daniel Bednarik

Daniel Bednárik, PhD
Visit website